Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELAY: Ramucirumab Plus Erlotinib in EGFR-Mutant Metastatic NSCLC
2024-514269-20-00Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Ramucirumab + erlotinib with Placebo + erlotinib (2 arms). Primary endpoints: Progression-free survival (PFS) in Part B (Placebo + erlotinib) and Number of participants with treatment-emergent adverse events. Started Aug 2024; status: completed.
02
Drugs
ramucirumaberlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-514269-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514269-20-00.